|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Akerley WL et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. Proc ASCO 2008;Abstract 8043.
Archer V et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. Proc ASCO 2008;Abstract 8114.
Gradishar WJ et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2007;Abstract 1032.
Labidi S et al. Bevacizumab and paclitaxel for breast cancer patients with CNS metastases. Proc ASCO 2008;Abstract 12009.
Mayer TM et al. A single institution’s experience with bevacizumab and cytotoxic chemotherapy in progressive malignant glioma. Proc ASCO 2008;Abstract 13010.
Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract
Narayana A et al. Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival. Proc ASCO 2008;Abstract 13000.
Olver IN. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: Choosing which patient and when. Future Oncol 2008;4(1):125-31. Abstract
Rich JN et al. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma. Proc ASCO 2008;Abstract 2022.
Rosner D et al. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58(4):832-9. Abstract
Rosner D et al. Management of brain metastases from breast cancer by combination chemotherapy. J Neurooncol 1983;1(2):131-7. Abstract
Saif MW et al. Capecitabine: An overview of the side effects and their management. Anticancer Drugs 2008;19(5):447-64. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Sledge G et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line therapy in metastatic breast cancer. Proc ASCO 2007;Abstract 1013.
Traina TA et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008;26(11):1797-802. Abstract
Vogel CL, Franco SX. Clinical experience with trastuzumab (Herceptin). Breast J 2003;9(6):452-62. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Vredenburgh JJ et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9. Abstract
 |
 |
EDITOR'S NOTE
Austrian tag team
Neil Love, MD
- Select publications
INTERVIEWS
Michael Gnant, MD
- Select publications
Hyman B Muss, MD
- Select publications
Matthew J Ellis, MB, BChir, PhD
- Select publications
Charles L Vogel, MD (Fellows Rounds)
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
